Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA ...

Each enfortumab vedotin and pembrolizumab have shown a survival benefit versus chemotherapy in UC, are not restricted by cisplatin eligibility, and warrant investigation as a first-line (1L ...

Treatment with enfortumab vedotin and pembrolizumab resulted in significantly better outcomes than chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma, with ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the European Commission has granted Marketing Authorization for PADCEV™ (enfortumab vedotin ...

Enfortumab vedotin (EV) is the first drug in this new class to be approved by the EMA at for the treatment of patients and patients with metastatic urothelial carcinoma.

Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial cancer, said Evangelia Vlachou, MD, of Johns Hopkins Medicine.

A target of enfortumab vedotin is Nectin-4, a molecule ordinarily expressed in skin, as well as various internal structures of the body. High expression of Nectin-4 is seen with many cancers.

The US Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) in combination with pembrolizumab (Keytruda) to treat locally advanced or metastatic urothelial ...

The NMPA accepted a BLA from Astellas Pharma Inc. for enfortumab vedotin, which is designed for the treatment of patients with locally advanced or metastatic urothelial cancer who previously received ...

The combination of pembrolizumab plus enfortumab vedotin significantly extended OS and PFS as first-line treatment for adults with locally advanced or metastatic urothelial carcinoma, according to ...

Discussion Enfortumab vedotin plus pembrolizumab is a 1L platinum-free regimen that showed promising antitumor activity and a manageable safety profile in cisplatin-ineligible patients, including ...